NCT01108679

Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: Albert Einstein College of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive. In addition, blood samples will be stored for HIV+ and HIV- individuals who take buprenorphine to study its effect. This study hypothesizes that the HIV positive participants will demonstrate significant improvement in thinking and reasoning ability at 3 and 6 months compared to baseline, but that their thinking and reasoning ability will still be lower than HIV negative participants. This study also hypothesizes the biomarkers in participants' blood samples will be associated with measures of change in thinking and reasoning ability.

Conditions

• Opioid-related Disorders
• Buprenorphine
• HIV
• Cognition
• HIV Infections

Timeline

• Start date: 2009-12-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2010-04-22
• Last updated: 2019-04-10

Locations

2 sites across 1 country: United States